EKSO Ekso Bionics Holdings, Inc.
USHealthcareAs of 2026-07-02 15:24
Why EKSO matters now
Ekso Bionics Holdings, Inc. (EKSO) is a US stock in Healthcare. The latest InvestLog snapshot shows $15.90 with -9.86% on the session and $38.6M in market capitalization; recent performance reads 1-month +50.51% and YTD +171.41%.
The latest financial table shown here is Q1 2026, with revenue of $2.1M, net income of $-6.9M, and EPS of $-2.04. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -21.1%.
The latest indexable market news headline is "ChronoScale Appoints Cenly Chen as Chief Executive Officer to Lead Next Phase of AI Compute Growth" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $3.50; recent insider activity includes Wong Jerome filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
14.56
P/S
4.92
EV/EBITDA
-4.29
DCF Value
$-89.38
FCF Yield
-21.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
52.9%
Operating Margin
-134.1%
Net Margin
-135.7%
ROE
-177.4%
ROA
-79.8%
ROIC
-108.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.1M | $-6.9M | $-2.04 |
| Q4 2025 | $3.1M | $-4.7M | $-1.57 |
| FY 2025 | $12.8M | $-11.7M | $-4.91 |
| Q3 2025 | $4.2M | $-1.4M | $-0.54 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$3.50
Target (Median)
$3.50
Target Range
$1.00 - $6.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US
Exchange
—
Beta
0.78
Ekso Bionics Holdings, Inc. is a global innovator in exoskeleton technology, specializing in the creation, production, sale, and leasing of these advanced devices across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. The company's operations are divided into two distinct segments: EksoHealth and EksoWorks. The EksoHealth division concentrates on engineering, manufacturing, and marketing exoskeletons designed for medical applications. Conversely, the EksoWorks segment develops and commercializes exoskeleton solutions intended for able-bodied individuals, empowering them to perform demanding, repetitive physical tasks for extended durations. Its product portfolio includes EksoNR, a sophisticated wearable bionic suit and rehabilitation tool. This device supports physical therapists and physicians in treating patients recovering from conditions such as acquired brain injury, stroke, and spinal cord injury. Additionally, the EksoUE is an assistive wearable device for the upper extremities, designed to lessen the gravitational load on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. also maintains a licensing agreement with Lockheed Martin Corporation. Founded in 2005, the company maintains its corporate headquarters in Richmond, California.